Standard General L.P. Insider in Standard Diversified Inc. (NYSEAMERICAN:SDI), Obtained 20,000 Shares; Celgene (CELG) Covered By 3 Bulls

Celgene Corporation (NASDAQ:CELG) Logo

Among 9 analysts covering Celgene (NASDAQ:CELG), 3 have Buy rating, 0 Sell and 6 Hold. Therefore 33% are positive. Celgene had 14 analyst reports since October 1, 2018 according to SRatingsIntel. The stock has “Buy” rating by Cantor Fitzgerald on Thursday, February 28. The firm has “Buy” rating given on Thursday, February 28 by Robert W. Baird. As per Thursday, February 28, the company rating was maintained by Jefferies. The stock of Celgene Corporation (NASDAQ:CELG) earned “Equal-Weight” rating by Morgan Stanley on Wednesday, December 19. The firm has “Buy” rating given on Tuesday, March 12 by Robert W. Baird. The rating was upgraded by Robert W. Baird on Friday, January 4 to “Outperform”. Goldman Sachs upgraded the stock to “Neutral” rating in Friday, January 4 report. As per Monday, December 17, the company rating was maintained by Citigroup. The stock of Celgene Corporation (NASDAQ:CELG) earned “Market Perform” rating by Wells Fargo on Friday, January 4. As per Friday, December 21, the company rating was reinitiated by BTIG Research. See Celgene Corporation (NASDAQ:CELG) latest ratings:

12/03/2019 Broker: Robert W. Baird Rating: Buy New Target: $101 Maintain
28/02/2019 Broker: Cantor Fitzgerald Rating: Buy New Target: $100 Maintain
28/02/2019 Broker: William Blair Rating: Buy Maintain
28/02/2019 Broker: Jefferies Rating: Buy New Target: $95 Maintain
28/02/2019 Broker: Robert W. Baird Rating: Buy New Target: $101 Maintain
26/02/2019 Broker: Cowen & Co Rating: Market Perform New Target: $102 Initiates Coverage On
01/02/2019 Broker: Jefferies Old Rating: Buy New Rating: Hold Downgrade
04/01/2019 Broker: Robert W. Baird Old Rating: Neutral New Rating: Outperform New Target: $92 Upgrade
04/01/2019 Broker: Wells Fargo Old Rating: Market Perform New Rating: Market Perform Old Target: $90 New Target: $84 Maintain
04/01/2019 Broker: Goldman Sachs Old Rating: Sell New Rating: Neutral Old Target: $71 New Target: $88 Upgrade

Standard Diversified Inc., through its subsidiaries, engages in the insurance, other tobacco products, and outdoor advertising activities in the United States. The company has market cap of $304.73 million. The firm operates in three divisions: Smokeless Products, Smoking Products, and NewGen Products. It has a 58.47 P/E ratio. It provides makes and sells a range of products across the over-the-counter market, including moist snuff tobaccos, loose leaf chewing tobaccos, premium cigarette papers, make-your-own cigar wraps and tobaccos, cigars, liquid vapor products, tobacco vaporizers, tubes, and related products; processes, packages, and markets pipe tobaccos; contracts for and markets chewing tobacco products; and markets e-cigarettes, e-liquids, vaporizers, and other related products.

More notable recent Standard Diversified Inc. (NYSEAMERICAN:SDI) news were published by: Insurancenewsnet.com which released: “Standard Diversified Inc. Reports Financial Results for Its Fourth Quarter and Year Ended December 31, 2018 – Insurance News Net” on March 12, 2019, also Businesswire.com with their article: “Standard Diversified Inc. Enters into Stock Purchase Agreement to Acquire Tri-State Consumer Insurance Co. – Business Wire” published on December 10, 2018, Businesswire.com published: “Standard Diversified Commences Trading on the NYSE American Exchange under the Symbol “SDI” – Business Wire” on April 25, 2018. More interesting news about Standard Diversified Inc. (NYSEAMERICAN:SDI) were released by: Businesswire.com and their article: “Standard Diversified Inc. Reports Financial Results for Its Third Quarter Ended September 30, 2018 – Business Wire” published on November 09, 2018 as well as Businesswire.com‘s news article titled: “Standard Diversified Subsidiary Turning Point Brands Acquires International Vapor Group, Inc. – Business Wire” with publication date: September 06, 2018.

The stock increased 19.87% or $3.48 during the last trading session, reaching $20.99. About 71,968 shares traded or 498.49% up from the average. Standard Diversified Inc. (NYSEAMERICAN:SDI) has 0.00% since March 14, 2018 and is . It has underperformed by 4.37% the S&P500.

Standard General L.P. – a famous insider in Standard Diversified Inc – paid for 20,000 shares of Standard Diversified Inc, worth approximately U.S Dollars 310,000 calculated with average price per share of U.S Dollars 15.5. Standard General L.P. now holds 7.36 million shares which are equivalent to around 50.70% of the Delaware-Company’s total market cap.

The stock increased 1.99% or $1.7 during the last trading session, reaching $87.3. About 105 shares traded. Celgene Corporation (NASDAQ:CELG) has declined 1.66% since March 14, 2018 and is downtrending. It has underperformed by 6.03% the S&P500. Some Historical CELG News: 12/04/2018 – The Klein Law Firm Reminds Investors of an Investigation Concerning Possible Violations of Federal Securities Laws by Celgene Corporation; 15/05/2018 – HHS Secretary Azar pitches naming and shaming tactics on drug price campaign, singling out Celgene’s Revlimid; 09/04/2018 – STAT Plus: Pharmalittle: Novartis pays $9 billion for gene therapy company; Merck’s Keytruda scores a win; 30/05/2018 – F-STAR: EARLY EXERCISE BY DENALI THERAPEUTICS OF OPTION TO BUY; 23/04/2018 – ZYMEWORKS INC – CELGENE CORP EXERCISED RIGHT TO EXPAND DEAL FOR COMMERCIALIZATION OF BISPECIFIC ANTIBODY THERAPEUTICS USING CO’S AZYMETRIC PLATFORM; 09/04/2018 – Keytruda is already approved to treat several forms of cancer, including advanced melanoma. The drug racked up $3.81 billion in revenue in 2017; 01/05/2018 – Keytruda sales power Merck to quarterly beat; 19/04/2018 – CELGENE CORP – GILLA KAPLAN RETIRING FROM BOARD OF DIRECTORS; 20/03/2018 – Prothena to Get $100 Million Upfront Payment and $50 Million Equity Investment by Celgene; 27/03/2018 – BMY: FDA GRANTED OPDIVO COMBO BREAKTHROUGH THERAPY DESIGNATION

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. The company has market cap of $61.32 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. It has a 15.84 P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

More notable recent Celgene Corporation (NASDAQ:CELG) news were published by: Nasdaq.com which released: “CELG vs. VRTX: Which Stock Is the Better Value Option? – Nasdaq” on March 13, 2019, also Nasdaq.com with their article: “Celgene (CELG) Gains But Lags Market: What You Should Know – Nasdaq” published on March 11, 2019, Seekingalpha.com published: “Celgene’s Abraxane flunks late-stage pancreatic cancer study – Seeking Alpha” on March 12, 2019. More interesting news about Celgene Corporation (NASDAQ:CELG) were released by: Nasdaq.com and their article: “Why Celgene Stock Dropped 9% Today – Nasdaq” published on February 28, 2019 as well as Nasdaq.com‘s news article titled: “Zacks.com featured expert Kevin Matras highlights: Sallie Mae, United Continental, Celgene and Ligand Pharmaceuticals – Nasdaq” with publication date: March 13, 2019.

Celgene Corporation (NASDAQ:CELG) Institutional Positions Chart